|
SG11201810171SA
(en)
|
2016-05-18 |
2018-12-28 |
Mirati Therapeutics Inc |
Kras g12c inhibitors
|
|
NZ754994A
(en)
|
2016-12-22 |
2022-12-23 |
Amgen Inc |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
JOP20190272A1
(ar)
*
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
|
PT3710439T
(pt)
|
2017-11-15 |
2023-05-15 |
Array Biopharma Inc |
Inibidores de kras g12c
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
WO2019110751A1
(en)
*
|
2017-12-08 |
2019-06-13 |
Astrazeneca Ab |
Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents
|
|
ES2969284T3
(es)
*
|
2018-01-19 |
2024-05-17 |
Medshine Discovery Inc |
Derivado de piridona-pirimidina que actúa como inhibidor de la muteína krasg12c
|
|
TW201942115A
(zh)
*
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
*
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
BR112020020307A2
(pt)
*
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MA52501A
(fr)
*
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
EP3802535B1
(en)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras g12c inhibitors and methods of using the same
|
|
MA51848A
(fr)
*
|
2018-06-12 |
2021-04-21 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
BR112021002772A2
(pt)
*
|
2018-08-16 |
2021-05-04 |
F. Hoffmann-La Roche Ag |
compostos, composições farmacêuticas, método de tratamento de câncer, métodos para regular a atividade de uma proteína, para inibir a proliferação de uma população de células, para tratar um distúrbio, para preparar uma proteína, para inibir metástase de tumor e para tratamento de câncer e usos
|
|
EP3844151B1
(en)
*
|
2018-08-31 |
2023-08-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
CA3111980A1
(en)
*
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3849537B1
(en)
*
|
2018-09-10 |
2024-10-23 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
IL281344B2
(en)
*
|
2018-09-10 |
2025-09-01 |
Mirati Therapeutics Inc |
Combination of adagrasib and cetuximab for cancer treatment
|
|
PT3849534T
(pt)
*
|
2018-09-10 |
2025-04-01 |
Mirati Therapeutics Inc |
Combinação de dasatinib e adagrasib para utilização no tratamento de cancro do pulmão de células não pequenas
|
|
JP2022500385A
(ja)
*
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
CN112996795B
(zh)
|
2018-09-18 |
2024-11-12 |
尼坎治疗公司 |
作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
|
|
CN114042070A
(zh)
|
2018-09-30 |
2022-02-15 |
凯瑞康宁生物工程（武汉）有限公司 |
作为神经元组胺受体-3拮抗剂的化合物及其用途
|
|
JP7451419B2
(ja)
|
2018-10-26 |
2024-03-18 |
大鵬薬品工業株式会社 |
新規なインダゾール化合物又はその塩
|
|
RS66280B1
(sr)
*
|
2018-11-09 |
2025-01-31 |
Hoffmann La Roche |
Jedinjenja sa kondenzovanim prstenovima
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
CA3112129A1
(en)
*
|
2018-12-05 |
2020-06-11 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
WO2020165732A1
(en)
|
2019-02-12 |
2020-08-20 |
Novartis Ag |
Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
|
|
CR20210504A
(es)
|
2019-03-05 |
2022-02-08 |
Astrazeneca Ab |
Compuestos tricíclicos condensados útiles como agentes anticancerígenos
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
US20220227738A1
(en)
*
|
2019-05-20 |
2022-07-21 |
California Institute Of Technology |
Kras g12c inhibitors and uses thereof
|
|
WO2020236948A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
EP3972973A1
(en)
|
2019-05-21 |
2022-03-30 |
Amgen Inc. |
Solid state forms
|
|
WO2020238791A1
(zh)
*
|
2019-05-24 |
2020-12-03 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
KR20220027879A
(ko)
*
|
2019-05-29 |
2022-03-08 |
상하이 한서 바이오메디컬 컴퍼니 리미티드 |
질소 함유 헤테로사이클릭 유도체의 조절제, 이의 제조방법 및 용도
|
|
CN112047939B
(zh)
*
|
2019-06-06 |
2023-05-02 |
江苏先声药业有限公司 |
一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物
|
|
CN114040914B
(zh)
*
|
2019-07-01 |
2024-10-22 |
江苏恒瑞医药股份有限公司 |
喹唑啉酮类衍生物、其制备方法及其在医药上的应用
|
|
CN112300153B
(zh)
*
|
2019-07-26 |
2023-06-13 |
博瑞生物医药（苏州）股份有限公司 |
一种杂环化合物、药物组合物和用途
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
CN112390797A
(zh)
*
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
CN112390796B
(zh)
*
|
2019-08-19 |
2023-06-27 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
CN112430234B
(zh)
*
|
2019-08-26 |
2023-04-28 |
信达生物制药(苏州)有限公司 |
一种新型kras g12c蛋白抑制剂及其制备方法和用途
|
|
AU2020337938B2
(en)
|
2019-08-29 |
2025-09-25 |
Array Biopharma Inc. |
KRas G12D inhibitors
|
|
CN114616232A
(zh)
*
|
2019-09-06 |
2022-06-10 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
WO2021055728A1
(en)
*
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
CN112538084B
(zh)
*
|
2019-09-23 |
2023-06-20 |
信达生物制药(苏州)有限公司 |
新颖的kras g12c蛋白抑制剂及其制备方法和用途
|
|
MX2022003537A
(es)
|
2019-09-24 |
2022-07-11 |
Mirati Therapeutics Inc |
Terapias de combinacion.
|
|
WO2021068898A1
(zh)
*
|
2019-10-10 |
2021-04-15 |
信达生物制药(苏州)有限公司 |
新颖的kras g12c蛋白抑制剂及其制备方法和用途
|
|
CN112694475B
(zh)
*
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
CR20220230A
(es)
|
2019-10-28 |
2022-06-15 |
Merck Sharp & Dohme |
Inhibidores de pequeñas moléculas de mutante g12c de kras
|
|
EP4054719B1
(en)
|
2019-11-04 |
2026-02-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP7823816B2
(ja)
|
2019-11-04 |
2026-03-04 |
レヴォリューション・メディスンズ，インコーポレイテッド |
Ｒａｓ阻害剤
|
|
KR20220109407A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
|
CN112778301A
(zh)
*
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
WO2021093758A1
(zh)
*
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
CN112824410A
(zh)
*
|
2019-11-21 |
2021-05-21 |
苏州泽璟生物制药股份有限公司 |
氮杂七元环类抑制剂及其制备方法和应用
|
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2021106231A1
(en)
*
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
US20220315598A1
(en)
*
|
2019-12-02 |
2022-10-06 |
Shanghai Yingli Pharmaceutical Co., Ltd |
Oxygen-containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof
|
|
CN112979664B
(zh)
*
|
2019-12-02 |
2024-03-01 |
上海璎黎药业有限公司 |
一种含氧杂环化合物、其制备方法及应用
|
|
EP4076418A4
(en)
|
2019-12-20 |
2024-01-24 |
Mirati Therapeutics, Inc. |
Sos1 inhibitors
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
CN112094269B
(zh)
*
|
2020-01-01 |
2021-12-07 |
上海凌达生物医药有限公司 |
一类饱和六元环并杂环类化合物、制备方法和用途
|
|
GB202001344D0
(en)
*
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
WO2021168193A1
(en)
*
|
2020-02-20 |
2021-08-26 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
|
CA3232127A1
(en)
*
|
2020-03-12 |
2021-09-16 |
D3 Bio (Wuxi) Co., Ltd. |
Pyrimidoheterocyclic compounds and application thereof
|
|
TWI811656B
(zh)
*
|
2020-04-22 |
2023-08-11 |
大陸商德昇濟醫藥（無錫）有限公司 |
嘧啶并雜環類化合物及其應用
|
|
TW202144349A
(zh)
*
|
2020-04-30 |
2021-12-01 |
大陸商上海科州藥物研發有限公司 |
作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
CN113666923A
(zh)
*
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
CN113683616B
(zh)
*
|
2020-05-18 |
2025-12-30 |
广州百霆医药科技有限公司 |
Kras g12c突变蛋白抑制剂
|
|
BR112022023462A2
(pt)
|
2020-06-02 |
2022-12-20 |
Boehringer Ingelheim Int |
2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncer
|
|
CN111646910A
(zh)
*
|
2020-06-15 |
2020-09-11 |
中国药科大学 |
一种盐酸达泊西汀消旋体的制备方法
|
|
CA3183032A1
(en)
|
2020-06-18 |
2021-12-23 |
Mallika Singh |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
|
CN115942936A
(zh)
|
2020-06-24 |
2023-04-07 |
勃林格殷格翰国际有限公司 |
包含sos1抑制剂和kras g12c抑制剂的抗癌组合疗法
|
|
CN113912608B
(zh)
*
|
2020-07-10 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
|
|
CN113980014B
(zh)
*
|
2020-07-27 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
US20250268901A1
(en)
|
2020-09-11 |
2025-08-28 |
Medshine Discovery Inc. |
Crystal form of azetidine-substituted compound
|
|
AU2021340716A1
(en)
|
2020-09-11 |
2023-03-30 |
Mirati Therapeutics, Inc. |
Crystalline forms of a KRas G12C inhibitor
|
|
CR20230165A
(es)
|
2020-09-15 |
2023-06-02 |
Revolution Medicines Inc |
Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
|
|
US20230357277A1
(en)
*
|
2020-09-22 |
2023-11-09 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
US12162893B2
(en)
|
2020-09-23 |
2024-12-10 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20230365563A1
(en)
*
|
2020-09-30 |
2023-11-16 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Quinazoline compound and application thereof
|
|
CA3195464A1
(en)
*
|
2020-10-14 |
2022-04-21 |
Weiwen Ying |
Methods and compositions for targeted protein degradation
|
|
UY39477A
(es)
|
2020-10-20 |
2022-05-31 |
Amgen Inc |
Compuestos espiro heterocíclicos y métodos de uso
|
|
WO2022087371A1
(en)
*
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel bicyclic compounds
|
|
WO2022087375A1
(en)
*
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel heterocyclic compounds
|
|
WO2022105855A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
KR102503336B1
(ko)
|
2020-11-23 |
2023-02-23 |
동의대학교 산학협력단 |
음성지원이 가능한 반려동물의 배변 처리 패드
|
|
WO2022109485A1
(en)
*
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
CN116829151A
(zh)
*
|
2020-12-15 |
2023-09-29 |
米拉蒂治疗股份有限公司 |
氮杂喹唑啉泛KRas抑制剂
|
|
AU2021401232A1
(en)
|
2020-12-15 |
2023-06-22 |
Mirati Therapeutics, Inc. |
Azaquinazoline pan-kras inhibitors
|
|
US11999753B2
(en)
*
|
2020-12-16 |
2024-06-04 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-KRas inhibitors
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
MX2023009037A
(es)
*
|
2021-02-01 |
2023-08-10 |
Medshine Discovery Inc |
Compuesto de pirimidopirano.
|
|
WO2022171143A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
|
|
WO2022170947A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
苏州阿尔脉生物科技有限公司 |
一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
|
|
CN116964057A
(zh)
*
|
2021-03-10 |
2023-10-27 |
贝达医药公司 |
作为kras抑制剂的吡啶并嘧啶衍生物
|
|
CN116801883A
(zh)
*
|
2021-03-18 |
2023-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
|
IL307392A
(en)
|
2021-04-08 |
2023-12-01 |
Mirati Therapeutics Inc |
Combination therapies with PRMT5 inhibitors for cancer treatment
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
WO2022214594A1
(en)
|
2021-04-09 |
2022-10-13 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
US20240228510A1
(en)
*
|
2021-04-16 |
2024-07-11 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
EP4322954A4
(en)
*
|
2021-04-16 |
2025-01-29 |
Merck Sharp & Dohme LLC |
SMALL MOLECULAR INHIBITORS OF THE KRAS G12D MUTANT
|
|
CN117203208A
(zh)
*
|
2021-04-23 |
2023-12-08 |
清华大学 |
靶向活化与失活态kras g12d的抑制剂
|
|
WO2022228543A1
(zh)
*
|
2021-04-30 |
2022-11-03 |
江苏恒瑞医药股份有限公司 |
桥环类化合物、其制备方法及其在医药上的应用
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
IL308193A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors
|
|
US12280055B2
(en)
|
2021-05-27 |
2025-04-22 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CN117769554A
(zh)
*
|
2021-05-28 |
2024-03-26 |
大鹏药品工业株式会社 |
Kras突变蛋白的小分子抑制剂
|
|
WO2022261210A1
(en)
*
|
2021-06-08 |
2022-12-15 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
CN117425649A
(zh)
|
2021-06-23 |
2024-01-19 |
诺华股份有限公司 |
作为kras突变蛋白抑制剂的吡唑衍生物
|
|
WO2022271823A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Newave Pharmaceutical Inc. |
Mutant kras modulators and uses thereof
|
|
WO2023280026A1
(zh)
*
|
2021-07-05 |
2023-01-12 |
四川科伦博泰生物医药股份有限公司 |
杂芳环化合物、其制备方法及用途
|
|
CA3224674A1
(en)
|
2021-07-07 |
2023-01-12 |
Pei Gan |
Tricyclic compounds as inhibitors of kras
|
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
CN117157292A
(zh)
*
|
2021-07-16 |
2023-12-01 |
苏州赞荣医药科技有限公司 |
Kras g12d抑制剂和其用途
|
|
WO2023283933A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Biotech Co., Ltd. |
Compounds useful as kras g12d inhibitors
|
|
CA3227706A1
(en)
|
2021-07-27 |
2023-02-02 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
TW202327569A
(zh)
|
2021-09-01 |
2023-07-16 |
瑞士商諾華公司 |
包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途
|
|
EP4389751A1
(en)
*
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CN117222646A
(zh)
*
|
2021-09-16 |
2023-12-12 |
苏州赞荣医药科技有限公司 |
Kras g12c抑制剂和其用途
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
AU2022371727A1
(en)
|
2021-10-22 |
2024-05-02 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
|
|
MX2024005228A
(es)
|
2021-11-05 |
2024-07-24 |
Frontier Medicines Corp |
Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
|
|
CN119841847A
(zh)
|
2021-12-01 |
2025-04-18 |
勃林格殷格翰国际有限公司 |
用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
|
|
WO2023098426A1
(zh)
*
|
2021-12-02 |
2023-06-08 |
上海和誉生物医药科技有限公司 |
一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用
|
|
JP7779584B2
(ja)
*
|
2021-12-02 |
2025-12-03 |
上海和誉生物医薬科技有限公司 |
Ｋｒａｓ阻害剤とその製造及び薬学における応用
|
|
JP2025500878A
(ja)
|
2021-12-17 |
2025-01-15 |
ジェンザイム・コーポレーション |
Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
|
|
JP2024546642A
(ja)
|
2021-12-22 |
2024-12-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんの処置のための複素芳香族化合物
|
|
CA3240772A1
(en)
|
2021-12-22 |
2023-06-29 |
Kevan M. Shokat |
Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
|
|
CN116410145A
(zh)
*
|
2021-12-29 |
2023-07-11 |
上海泓博智源医药股份有限公司 |
一种mrtx849中间体的制备方法
|
|
CN118434740A
(zh)
*
|
2021-12-31 |
2024-08-02 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
WO2023137223A1
(en)
*
|
2022-01-17 |
2023-07-20 |
Newave Pharmaceutical Inc. |
Pan-kras inhibitors and uses thereof
|
|
CN118556063A
(zh)
*
|
2022-01-21 |
2024-08-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
IL314812A
(en)
|
2022-02-09 |
2024-10-01 |
Quanta Therapeutics Inc |
Kras modulators and uses thereof
|
|
CN118696046A
(zh)
|
2022-02-10 |
2024-09-24 |
拜耳公司 |
作为kras抑制剂的稠合嘧啶
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
CN116891514A
(zh)
*
|
2022-04-06 |
2023-10-17 |
润佳（苏州）医药科技有限公司 |
一种双官能化合物及其用途
|
|
IL315603A
(en)
|
2022-03-28 |
2024-11-01 |
Nikang Therapeutics Inc |
Sulfonamido derivatives as cycle-dependent KINASE 2 inhibitors
|
|
JP2025511161A
(ja)
|
2022-04-04 |
2025-04-15 |
サノフイ |
Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
CN116891488B
(zh)
*
|
2022-04-11 |
2025-12-12 |
成都海博为药业有限公司 |
稠环化合物、包含其的药物组合物及应用
|
|
WO2023220421A1
(en)
*
|
2022-05-13 |
2023-11-16 |
Ranok Therapeutics (Hangzhou) Co. Ltd. |
Inhibitors of kras(g12d)
|
|
KR20250034204A
(ko)
|
2022-05-25 |
2025-03-10 |
콴타 테라퓨틱스, 인크. |
피리미딘 기반 조절인자 및 이의 용도
|
|
CN117164580A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
一种kras g12c抑制剂的制备方法及其中间体
|
|
EP4536363A1
(en)
|
2022-06-08 |
2025-04-16 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN119677748A
(zh)
*
|
2022-06-14 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
氢吡啶并嘧啶泛KRas抑制剂
|
|
WO2023244615A1
(en)
*
|
2022-06-15 |
2023-12-21 |
Mirati Therapeutics, Inc. |
Azaquinazoline pan-kras inhibitors
|
|
GB202212641D0
(en)
|
2022-08-31 |
2022-10-12 |
Jazz Pharmaceuticals Ireland Ltd |
Novel compounds
|
|
TW202428280A
(zh)
*
|
2022-09-28 |
2024-07-16 |
美商米拉蒂醫療公司 |
組合療法
|
|
WO2024081674A1
(en)
|
2022-10-11 |
2024-04-18 |
Aadi Bioscience, Inc. |
Combination therapies for the treatment of cancer
|
|
AU2023377064A1
(en)
|
2022-11-09 |
2025-05-22 |
Revolution Medicines, Inc. |
Compounds, complexes, and methods for their preparation and of their use
|
|
TW202434563A
(zh)
|
2022-11-11 |
2024-09-01 |
美商尼坎醫療公司 |
用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２的含有２，５－取代的嘧啶衍生物之雙功能化合物
|
|
AU2024212035A1
(en)
|
2023-01-26 |
2025-08-14 |
Arvinas Operations, Inc. |
Cereblon-based kras degrading protacs ans uses related thereto
|
|
WO2024192424A1
(en)
|
2023-03-15 |
2024-09-19 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
PE20260039A1
(es)
|
2023-04-07 |
2026-01-09 |
Revolution Medicines Inc |
Inhibidores macrociclicos de ras
|
|
TW202448897A
(zh)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
KR20240168510A
(ko)
*
|
2023-05-22 |
2024-12-02 |
주식회사 이노파마스크린 |
Kras g12d 및 g12v 돌연변이 표적 화합물 및 그 용도
|
|
CN116640104B
(zh)
*
|
2023-05-24 |
2024-04-02 |
杭州科耀医药科技有限公司 |
一种替洛利生的工业合成方法
|
|
TW202510886A
(zh)
|
2023-05-31 |
2025-03-16 |
德商百靈佳殷格翰國際股份有限公司 |
作為用於預測癌症治療反應性之生物標記之存活素
|
|
KR20260020406A
(ko)
|
2023-06-02 |
2026-02-11 |
다이이찌 산쿄 가부시키가이샤 |
항 her3 항체-약물 콘주게이트와 rasg12c 저해제의 조합
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
TW202529768A
(zh)
|
2023-09-29 |
2025-08-01 |
大陸商德昇濟醫藥（無錫）有限公司 |
癌症治療的療法
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
TW202535891A
(zh)
|
2023-10-20 |
2025-09-16 |
美商默沙東有限責任公司 |
Ｋｒａｓ蛋白之小分子抑制劑
|
|
WO2025117616A1
(en)
|
2023-11-27 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025117981A1
(en)
|
2023-12-02 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
WO2025132549A1
(en)
|
2023-12-20 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Cancer combination therapy using zongertinib and a kras g12c inhibitor
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026003808A1
(en)
|
2024-06-28 |
2026-01-02 |
Assia Chemical Industries Ltd. |
Solid state form of adagrasib and process for preparation
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|